| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Retrospective Study |
| Article Title |
Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Martha Grogan, Morie Gertz, Arleigh McCurdy, Lindsey Roeker, Robert Kyle, Sudhir Kushwaha, Richard Daly, Joseph Dearani, Richard Rodeheffer, Robert Frantz, Martha Lacy, Suzanne Hayman, Christopher McGregor, Brooks Edwards and Angela Dispenzieri |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Martha Grogan, MD, Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. grogan.martha@mayo.edu
|
| Key Words |
Heart transplantation; Autologous stem cell transplantation; Amyloidosis; Chemotherapy; Heart failure |
| Core Tip |
Heart failure due to immunoglobulin light chain (AL) amyloidosis is a devastating disease with poor prognosis. Orthotopic heart transplantation (OHT) is controversial. Twenty-three patients with AL amyloid underwent OHT at our institution over a twenty-year period. Median survival was 3.5 years following OHT. Median survival of seven patients who achieved a complete hematologic response to treatment for AL was almost 11 years. This study demonstrates that long term survival after heart transplant is feasible in AL patients with limited extra-cardiac involvement who achieve complete hematologic response.
|
| Publish Date |
2016-06-22 16:18 |
| Citation |
Grogan M, Gertz M, McCurdy A, Roeker L, Kyle R, Kushwaha S, Daly R, Dearani J, Rodeheffer R, Frantz R, Lacy M, Hayman S, McGregor C, Edwards B, Dispenzieri A. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant 2016; 6(2): 380-388 |
| URL |
http://www.wjgnet.com/2220-3230/full/v6/i2/380.htm |
| DOI |
http://dx.doi.org/10.5500/wjt.v6.i2.380 |
